Skip to main content

Articles

Page 2 of 48

  1. The Food and Drug Administration has approved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia. However, evidence of the optimal PCSK9 agents targeting PCSK9 f...

    Authors: Xing Wang, Dingke Wen, Yuqi Chen, Lu Ma and Chao You
    Citation: Cardiovascular Diabetology 2022 21:107
  2. Empagliflozin has been reported to protect endothelial cell function, regardless of diabetes status. However, the role of empagliflozin in microvascular protection during myocardial ischemia reperfusion injury...

    Authors: Rongjun Zou, Wanting Shi, Junxiong Qiu, Na Zhou, Na Du, Hao Zhou, Xinxin Chen and Li Ma
    Citation: Cardiovascular Diabetology 2022 21:106
  3. Recent studies have suggested that triglyceride-glucose (TyG) index is an independent predictor of cardiovascular disease (CVD). However, the impact of long-term visit-to-visit variability in TyG index on the ...

    Authors: Haibin Li, Yingting Zuo, Frank Qian, Shuohua Chen, Xue Tian, Penglian Wang, Xia Li, Xiuhua Guo, Shouling Wu and Anxin Wang
    Citation: Cardiovascular Diabetology 2022 21:105
  4. Type-2 diabetes (T2D), chronic kidney disease, and heart failure (HF) share epidemiological and pathophysiological features. Although their prevalence was described, there is limited contemporary, high-resolut...

    Authors: Meir Schechter, Cheli Melzer Cohen, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick, Johan Bodegård, Lawrence A. Leiter, Subodh Verma, Hiddo J. Lambers Heerspink, Avraham Karasik and Ofri Mosenzon
    Citation: Cardiovascular Diabetology 2022 21:104
  5. Coronary artery disease (CAD) detection in asymptomatic patients still remains controversial. The aim of our study was to evaluate the usefulness of ophthalmologic findings as predictors of the presence of CAD...

    Authors: José Lorenzo Romero-Trevejo, Lourdes Fernández-Romero, Josué Delgado, Erika Muñoz-García, Andrés Sánchez-Pérez, Mora Murri, Mario Gutiérrez-Bedmar and Manuel Francisco Jiménez-Navarro
    Citation: Cardiovascular Diabetology 2022 21:103
  6. Assessing the spectrum of disease risk associated with hypertriglyceridemia is needed to inform potential benefits from emerging triglyceride lowering treatments. We sought to examine the associations between ...

    Authors: Riyaz S. Patel, Laura Pasea, Handrean Soran, Paul Downie, Richard Jones, Aroon D. Hingorani, Dermot Neely, Spiros Denaxas and Harry Hemingway
    Citation: Cardiovascular Diabetology 2022 21:102
  7. Heart failure (HF) is a growing complication and one of the leading causes of mortality in people living with type 2 diabetes (T2D). Among the possible causes, the excess of red meat and the insufficiency of v...

    Authors: Matthieu Wargny, Mikaël Croyal, Stéphanie Ragot, Elise Gand, David Jacobi, Jean-Noël Trochu, Xavier Prieur, Cédric Le May, Thomas Goronflot, Bertrand Cariou, Pierre-Jean Saulnier and Samy Hadjadj
    Citation: Cardiovascular Diabetology 2022 21:101
  8. Functional mitral regurgitation (FMR) in type 2 diabetes mellitus (T2DM) patients induced by left ventricular (LV) enlargement and mitral valve abnormality may aggravated the impairment in left atrial (LA) com...

    Authors: Yi Zhang, Xue-Ming Li, Meng-Ting Shen, Shan Huang, Yuan Li and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2022 21:100
  9. Endothelin-1 (ET-1) and adrenomedullin (ADM) are commonly known as vasoactive peptides that regulate vascular homeostasis. Less recognised is the fact that both peptides could affect glucose metabolism. Here, ...

    Authors: Chaterina Sujana, Veikko Salomaa, Frank Kee, Jochen Seissler, Pekka Jousilahti, Charlotte Neville, Cornelia Then, Wolfgang Koenig, Kari Kuulasmaa, Jaakko Reinikainen, Stefan Blankenberg, Tanja Zeller, Christian Herder, Ulrich Mansmann, Annette Peters and Barbara Thorand
    Citation: Cardiovascular Diabetology 2022 21:99
  10. The association between osteocalcin and mortality has been scantly studied. We aimed to investigate the association between osteocalcin along with its trajectories and mortality based on long-term longitudinal...

    Authors: Yun Shen, Lei Chen, Jian Zhou, Chunfang Wang, Fei Gao, Wei Zhu, Gang Hu, Xiaojing Ma, Han Xia and Yuqian Bao
    Citation: Cardiovascular Diabetology 2022 21:98
  11. Arterial stiffness is a potential biomarker for cardiovascular disease (CVD) risk in patients with type 1 diabetes (T1D). However, its relation with other CV risk evaluation tools in T1D has not been elucidate...

    Authors: Simon Helleputte, Luc Van Bortel, Francis Verbeke, Jos Op ‘t Roodt, Patrick Calders, Bruno Lapauw and Tine De Backer
    Citation: Cardiovascular Diabetology 2022 21:97
  12. Triglyceride glucose (TyG) index is a new marker associated with atherosclerosis. This study aimed to assess the association between TyG index and the severity of coronary artery disease (CAD) in patients with...

    Authors: Jinyu Su, Zhu Li, Mengnan Huang, Yang Wang, Tong Yang, Mei Ma, Tongyao Ni, Guangwei Pan, Ziqin Lai, Chunjie Li, Lin Li and Chunquan Yu
    Citation: Cardiovascular Diabetology 2022 21:96
  13. Advanced glycation end-products (AGEs) and their interaction with the receptor for advanced glycation end-products (RAGE) play a pivotal role in the development and progression of type 2 diabetes. In this retr...

    Authors: Jacopo Sabbatinelli, Stefania Castiglione, Federica Macrì, Angelica Giuliani, Deborah Ramini, Maria Cristina Vinci, Elena Tortato, Anna Rita Bonfigli, Fabiola Olivieri and Angela Raucci
    Citation: Cardiovascular Diabetology 2022 21:95
  14. Type 2 diabetes mellitus (T2DM) increases the risk of worse long-term outcomes in patients with non-ischemic dilated cardiomyopathy (NIDCM). However, the additive effects of T2DM on left ventricular (LV) funct...

    Authors: Meng-Ting Shen, Yuan Li, Ying-Kun Guo, Li Jiang, Yue Gao, Rui Shi and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2022 21:94
  15. Type 2 diabetes mellitus (T2DM) is often accompanied by undiagnosed dyslipidemia. Research on the association of unconventional lipid markers with prediabetes (pre-DM) and T2DM simultaneously is limited in cor...

    Authors: Tong Yang, Yijia Liu, Lin Li, Yanchao Zheng, Yang Wang, Jinyu Su, Rongrong Yang, Mingchi Luo and Chunquan Yu
    Citation: Cardiovascular Diabetology 2022 21:93
  16. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have proven cardiovascular benefits in patients with type 2 diabetes (T2D). This self-controlled case series study aims to evaluate whether metformin use and ...

    Authors: Carlos King Ho Wong, Kristy Tsz Kwan Lau, Eric Ho Man Tang, Chi Ho Lee, Carmen Yu Yan Lee, Yu Cho Woo, Ivan Chi Ho Au, Kathryn Choon Beng Tan and David Tak Wai Lui
    Citation: Cardiovascular Diabetology 2022 21:92
  17. Red blood cell distribution width (RDW) has emerged as a prognostic factor for mortality in various diseases. Up to now, few studies have focused on the prognostic value of RDW in patients with diabetic foot u...

    Authors: Jing Hong, Xiang Hu, Wenyue Liu, Xuehua Qian, Feifei Jiang, Zeru Xu, Feixia Shen and Hong Zhu
    Citation: Cardiovascular Diabetology 2022 21:91
  18. To determine the impact of metabolic syndrome (MetS) and/or metabolic dysfunction-associated fatty liver disease (MAFLD), which are pathophysiologically similar and include insulin resistance, on the developme...

    Authors: Yasuhiro Matsubayashi, Kazuya Fujihara, Mayuko Yamada-Harada, Yurie Mitsuma, Takaaki Sato, Yuta Yaguchi, Taeko Osawa, Masahiko Yamamoto, Masaru Kitazawa, Takaho Yamada, Satoru Kodama and Hirohito Sone
    Citation: Cardiovascular Diabetology 2022 21:90
  19. Cardiovascular prognosis related to type 2 diabetes may not be adequately captured by information on comorbid conditions such as obesity and hypertension. To inform the cardiovascular prognosis among diabetic ...

    Authors: Justin B. Echouffo-Tcheugui, Solomon K. Musani, Alain G. Bertoni, Adolfo Correa, Ervin R. Fox and Robert J. Mentz
    Citation: Cardiovascular Diabetology 2022 21:89
  20. The triglyceride glucose (TyG) index has been proposed as a reliable marker of insulin resistance (IR) and an independent predictor of cardiovascular disease risk. However, its prognostic value in patients wit...

    Authors: Rong Huang, Ziyan Wang, Jianzhou Chen, Xue Bao, Nanjiao Xu, Simin Guo, Rong Gu, Weimin Wang, Zhonghai Wei and Lian Wang
    Citation: Cardiovascular Diabetology 2022 21:88
  21. Patients diagnosed with ischemic heart disease (IHD) are becoming increasingly multi-morbid, and studies designed to analyze the full spectrum are few.

    Authors: Amalie D. Haue, Jose J. Almagro Armenteros, Peter C. Holm, Robert Eriksson, Pope L. Moseley, Lars V. Køber, Henning Bundgaard and Søren Brunak
    Citation: Cardiovascular Diabetology 2022 21:87
  22. Hemoglobin A1C (HbA1c) is a form of glycated hemoglobin used to estimate glycemic control in diabetic patients. Data regarding the prognostic significance of HbA1c levels in contemporary intensive cardiac care...

    Authors: Lior Lupu, Louay Taha, Rivka Farkash, Feras Bayya, Mohammad Karmi, Yoed Steinmetz, Fauzi Fadi Shaheen, Nimrod Perel, Kamal Hamayel, Nir Levi, Tommer Maller, Hani Karameh, Gavriel Lichewitz, Dov Gavish, Nurit Algur, Michael Glikson…
    Citation: Cardiovascular Diabetology 2022 21:86
  23. Type 2 diabetes (T2D) and hypertension commonly coexist and are associated with subclinical myocardial structural and functional changes. We sought to determine the association between blood pressure (BP) and ...

    Authors: Jian L. Yeo, Gaurav S. Gulsin, Emer M. Brady, Abhishek Dattani, Joanna M. Bilak, Anna-Marie Marsh, Manjit Sian, Lavanya Athithan, Kelly S. Parke, Joanne Wormleighton, Matthew P. M. Graham-Brown, Anvesha Singh, J. Ranjit Arnold, Claire Lawson, Melanie J. Davies, Hui Xue…
    Citation: Cardiovascular Diabetology 2022 21:85
  24. Statin treatment increases the risk of new-onset diabetes mellitus (NODM); however, data directly comparing the risk of NODM among individual statins is limited. We compared the risk of NODM between patients u...

    Authors: Won-Woo Seo, Seung In Seo, Yerim Kim, Jong Jin Yoo, Woon Geon Shin, Jinseob Kim, Seng Chan You, Rae Woong Park, Young Min Park, Kyung-Jin Kim, Sang Youl Rhee, Meeyoung Park, Eun-Sun Jin and Sung Eun Kim
    Citation: Cardiovascular Diabetology 2022 21:82
  25. The atherogenic index of plasma (AIP) is composed of triglycerides and high-density lipoprotein cholesterol and is a novel marker for assessing the risk of atherogenicity and cardiometabolic health. An associa...

    Authors: Si Hyoung Kim, Yun Kyung Cho, Ye-Jee Kim, Chang Hee Jung, Woo Je Lee, Joong-Yeol Park, Ji Hye Huh, Jun Goo Kang, Seong Jin Lee and Sung-Hee Ihm
    Citation: Cardiovascular Diabetology 2022 21:81
  26. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be predictive of cardiovascular outcomes in stable coronary artery disease with diabetes. We aimed to assess the relationship between PCS...

    Authors: Li Song, Xiaoxiao Zhao, Runzhen Chen, Jiannan Li, Jinying Zhou, Chen Liu, Peng Zhou, Ying Wang, Yi Chen, Hanjun Zhao and Hongbing Yan
    Citation: Cardiovascular Diabetology 2022 21:80
  27. In patients with type 2 diabetes mellitus (T2DM) an association between severe hypoglycaemic episodes and the risk of cardiovascular (CV) morbidity and mortality has been previously established.

    Authors: Ceren Eyileten, Zofia Wicik, Disha Keshwani, Faisal Aziz, Felix Aberer, Peter N. Pferschy, Norbert J. Tripolt, Caren Sourij, Barbara Prietl, Florian Prüller, Dirk von Lewinski, Salvatore De Rosa, Jolanta M. Siller-Matula, Marek Postula and Harald Sourij
    Citation: Cardiovascular Diabetology 2022 21:79
  28. There have been scarce data comparing cardiovascular outcomes between individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the subsequent cardiovascular risk between individual SGL...

    Authors: Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga and Issei Komuro
    Citation: Cardiovascular Diabetology 2022 21:67
  29. Weight management is strongly promoted for overweight or obese patients with type 2 diabetes (T2DM) by current guidelines. However, the prognostic impact of weight loss achieved without behavioural interventio...

    Authors: Shan Huang, Ke Shi, Yan Ren, Jin Wang, Wei-Feng Yan, Wen-Lei Qian, Zhi-Gang Yang and Yuan Li
    Citation: Cardiovascular Diabetology 2022 21:78
  30. The inflammatory response occurring in acute myocardial infarction (AMI) has been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense ...

    Authors: Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, Emanuele Gallinoro, Arturo Cesaro, Felice Gragnano, Celestino Sardu, Niya Mileva, Alberto Foà, Matteo Armillotta, Angelo Sansonetti, Sara Amicone, Andrea Impellizzeri, Gianni Casella, Ciro Mauro, Dobrin Vassilev…
    Citation: Cardiovascular Diabetology 2022 21:77
  31. The prognostic importance of changes in aortic stiffness for the occurrence of adverse cardiovascular outcomes and mortality has never been investigated in patients with type 2 diabetes. We aimed to evaluate i...

    Authors: Claudia R L Cardoso, Nathalie C Leite and Gil Fernando Salles
    Citation: Cardiovascular Diabetology 2022 21:76
  32. The relationships between glucose abnormalities, insulin resistance (IR) and heart failure (HF) are unclear, especially regarding to the HF type, i.e., HF with reduced (HFrEF) or preserved (HFpEF) ejection fra...

    Authors: Tran Kim Son, Ngo Hoang Toan, Nguyen Thang, Huynh Le Trong Tuong, Hoang Anh Tien, Nguyen Hai Thuy, Huynh Van Minh and Paul Valensi
    Citation: Cardiovascular Diabetology 2022 21:75
  33. Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs ...

    Authors: Cheng-Xu Ma, Xiao-Ni Ma, Cong-Hui Guan, Ying-Dong Li, Dídac Mauricio and Song-Bo Fu
    Citation: Cardiovascular Diabetology 2022 21:74
  34. Individuals with type 2 diabetes mellitus (T2DM) have an increased risk for developing macrovascular disease (MVD) manifested by atherosclerosis. Phenotypically and functionally different monocyte subsets (cla...

    Authors: M. Reijrink, J. van Ark, C. P. H. Lexis, L. M. Visser, M. E. Lodewijk, I. C. C. van der Horst, C. J. Zeebregts, H. van Goor, S. C. A. de Jager, G. Pasterkamp, B. H. R. Wolffenbuttel and J. L. Hillebrands
    Citation: Cardiovascular Diabetology 2022 21:72
  35. Cardiovascular disease (CVD) and nontraumatic lower-limb amputation (LLA) each results in reduced life expectancy in patients with type 1 diabetes, but the differential burden between these conditions is unkno...

    Authors: Marion Camoin, Gilberto Velho, Pierre-Jean Saulnier, Louis Potier, Yawa Abouleka, Charlyne Carpentier, Severine Dubois, Alice Larroumet, Vincent Rigalleau, Elise Gand, Olivier Bourron, Lyse Bordier, André Scheen, Samy Hadjadj, Ronan Roussel, Michel Marre…
    Citation: Cardiovascular Diabetology 2022 21:71
  36. Diabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-related clinical entities. Biomarker profiling emerges as a promising tool for the early diagnosis and risk stratification of either DM...

    Authors: Efstratios Karagiannidis, Dimitrios V. Moysidis, Andreas S. Papazoglou, Eleftherios Panteris, Olga Deda, Nikolaos Stalikas, Georgios Sofidis, Anastasios Kartas, Alexandra Bekiaridou, George Giannakoulas, Helen Gika, George Theodoridis and Georgios Sianos
    Citation: Cardiovascular Diabetology 2022 21:70
  37. Heart failure with reduced ejection fraction (HFrEF) is a major health burden worldwide with high morbidity and mortality. Comorbidities of HFrEF complicate treatment and lead to poor prognosis, among which hy...

    Authors: Ge Zhang, Ke Shi, Wei-Feng Yan, Xue-Ming Li, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2022 21:69
  38. A single measurement of the triglyceride-glucose (TyG) index, a simple and reliable surrogate marker of insulin resistance, is associated with ischemic stroke. However, evidence for an effect of a long-term el...

    Authors: Xianxuan Wang, Baoyu Feng, Zegui Huang, Zefeng Cai, Xinran Yu, Zekai Chen, Zhiwei Cai, Guanzhi Chen, Shouling Wu and Youren Chen
    Citation: Cardiovascular Diabetology 2022 21:66
  39. We examined trends in incidence (2001–2019), clinical characteristics, and in-hospital outcomes following major and minor lower extremity amputations (LEAs) among type 1 diabetes mellitus (T1DM) patients in Sp...

    Authors: Ana Lopez-de-Andres, Rodrigo Jimenez-Garcia, Valentín Hernández-Barrera, Javier de-Miguel-Diez, José M. de-Miguel-Yanes, Ricardo Omaña-Palanco and David Carabantes-Alarcon
    Citation: Cardiovascular Diabetology 2022 21:65
  40. Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other ...

    Authors: Mansoor Husain, Agostino Consoli, Alessandra De Remigis, Anna Sina Pettersson Meyer, Søren Rasmussen and Stephen Bain
    Citation: Cardiovascular Diabetology 2022 21:64
  41. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been o...

    Authors: Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H. H. Kramer, Max Nieuwdorp and Richard G. IJzerman
    Citation: Cardiovascular Diabetology 2022 21:63
  42. Atherosclerotic cardiovascular diseases (CVD) is the leading cause of death in diabetes, but the full range of biomarkers reflecting atherosclerotic burden and CVD risk in people with diabetes is unknown. Meta...

    Authors: Zhe Huang, Lucija Klaric, Justina Krasauskaite, Stela McLachlan, Mark W. J. Strachan, James F. Wilson and Jackie F. Price
    Citation: Cardiovascular Diabetology 2022 21:62
  43. Individuals with type 2 diabetes have a substantially elevated cardiovascular risk. A higher plasma phosphate level promotes vascular calcification, which may adversely affect outcomes in individuals with type...

    Authors: Amarens van der Vaart, Qingqing Cai, Ilja M. Nolte, André P. J. van Beek, Gerjan Navis, Stephan J. L. Bakker, Peter R. van Dijk and Martin H. de Borst
    Citation: Cardiovascular Diabetology 2022 21:61
  44. Sleep duration is associated with mortality. However, prior studies exploring whether sleep duration predicts subsequent long-term mortality in patients with diabetes are limited. This study aims to examine wh...

    Authors: Chia-Ing Li, Cheng-Chieh Lin, Chiu-Shong Liu, Chih-Hsueh Lin, Shing-Yu Yang and Tsai-Chung Li
    Citation: Cardiovascular Diabetology 2022 21:60
  45. We aimed to study the cumulative incidence and risk factors (sex, age, calendar year of diabetes onset, country of origin and educational level) of acute myocardial infarction (AMI) in subjects with type 1 dia...

    Authors: Maryam Saeed, Lars C. Stene, Inger Ariansen, Grethe S. Tell, German Tapia, Geir Joner and Torild Skrivarhaug
    Citation: Cardiovascular Diabetology 2022 21:59
  46. Evidence to guide type 2 diabetes treatment individualization is limited. We evaluated heterogeneous treatment effects (HTE) of intensive glycemic control in type 2 diabetes patients on major adverse cardiovas...

    Authors: Justin A. Edward, Kevin Josey, Gideon Bahn, Liron Caplan, Jane E. B. Reusch, Peter Reaven, Debashis Ghosh and Sridharan Raghavan
    Citation: Cardiovascular Diabetology 2022 21:58

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics